Biotech Values

[mcbio]

Correct, according to the closing price today on the TASE.

Surprised it's so small given the potentially novel schizophrenia drug (BL-1020) in Phase 2/3. I would think that alone might merit a much higher market cap given potential and results to date. They also have several other drugs in their pipeline (http://www.biolinerx.com/default.asp?pageid=18 ) but I don't know much about them and whether it's just a case of quantity without any quality.